Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation

GM-CSF promotes migration of human monocytes across the blood brain barrier

(2015) Daphne Y. S. Vogel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Discovery of Small Molecule CD40–TRAF6 Inhibitors

(2015) Barbara Zarzycka et al.   Journal of Chemical Information and Modeling

Trichuris suis induces human non-classical patrolling monocytes via the mannose receptor and PKC: implications for multiple sclerosis

(2015) Gijs Kooij et al.   Acta Neuropathologica Communications

Role of the Blood–Brain Barrier in Multiple Sclerosis

(2014) Genaro Gabriel Ortiz et al.   ARCHIVES OF MEDICAL RESEARCH

The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human macrophages

(2014) M K Ottow et al.   GENES AND IMMUNITY

Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance

(2014) A. Chatzigeorgiou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?

(2013) Jörg Kreuter   ADVANCED DRUG DELIVERY REVIEWS

Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status

(2013) Daphne YS Vogel et al.   Journal of Neuroinflammation

Dyad of CD40/CD40 Ligand Fosters Neuroinflammation at the Blood-Brain Barrier and Is Regulated via JNK Signaling: Implications for HIV-1 Encephalitis

(2013) S. H. Ramirez et al.   JOURNAL OF NEUROSCIENCE

Development, maintenance and disruption of the blood-brain barrier

(2013) Birgit Obermeier et al.   NATURE MEDICINE

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

(2012) William Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

The innate immune system in demyelinating disease

(2012) Lior Mayo et al.   IMMUNOLOGICAL REVIEWS

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

(2012) David H Miller et al.   LANCET NEUROLOGY

Will the real multiple sclerosis please stand up?

(2012) Peter K. Stys et al.   NATURE REVIEWS NEUROSCIENCE

Radical changes in multiple sclerosis pathogenesis

(2010) Jack van Horssen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis

(2010) Gijs Kooij et al.   BRAIN

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

(2010) M. Hussein et al.   HAEMATOLOGICA

Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile

(2010) Esther Lutgens et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration

(2010) Joanna Mikita et al.   Multiple Sclerosis Journal

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

CD40 and autoimmunity: The dark side of a great activator

(2009) Anna L. Peters et al.   SEMINARS IN IMMUNOLOGY

The immunobiology of CD154–CD40–TRAF interactions in atherosclerosis

(2009) David Engel et al.   SEMINARS IN IMMUNOLOGY

The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling

(2008) M. M. P. C. Donners et al.   BLOOD

Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing–remitting multiple sclerosis

(2007) Robert Zivadinov et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES